OncoMatch/Clinical Trials/NCT06248606
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Is NCT06248606 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Adagrasib for non small cell lung cancer.
Treatment: Adagrasib — This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS g12c
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: KRAS G12C tyrosine kinase inhibitor
Prior treatment with KRAS G12C tyrosine kinase inhibitor.
Lab requirements
Blood counts
Hemoglobin (Hgb): ≥ 8.0 g/dL in the absence of transfusions within 7 days prior to testing.
Kidney function
Calculated creatinine clearance ≥ 60 mL/min
Liver function
Bilirubin ≤ 1.5 mg/dL; AST ≤ 3.0 × ULN; ALT ≤ 3.0 × ULN
Demonstrate adequate organ function as defined below. ... Hemoglobin (Hgb): ≥ 8.0 g/dL ... Calculated creatinine clearance: ≥ 60 mL/min ... Bilirubin: ≤ 1.5 mg/dL ... AST: ≤ 3.0 × ULN ... ALT: ≤ 3.0 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
- University of Virginia Health System · Charlottesville, Virginia
- Virginia Commonwealth University · Richmond, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06248606 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior KRAS G12C tyrosine kinase inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS g12c is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify